New Antibiotics. Will Roland, MD
|
|
- Annabel Floyd
- 6 years ago
- Views:
Transcription
1 New Antibiotics Will Roland, MD
2 FDA Approvals ceftaroline fidaxomicin, telaprevir, boceprevir, spinosad 2012 bedaquiline, raxibacumab, Stribild, 2013 sofosbuvir, simeprevir, dolutegravir 2014 peramivir, ceftolozane/tazobactam, Viekira Pak, Harvoni, oritavancin, tedizolid, dalbavancin, miltefosine, Jublia, Kerydin 2015 daclatasvir, ceftazidime-avibactam 2016 obiltoxaximab, elbasvir and grazoprevir, sofosbuvir and velpatasvir
3 ABSSSIs and CABP Ceftaroline (Teflaro) Binds to PBPs inhibiting cell wall synthesis High affinity for PBP2a - associated w/ methicillin resistance Consistently active against MDR Strep. pneumoniae and S. aureus Methicillin-resistant, vancomycin-intermediate, linezolid-resistant, daptomycin-nonsusceptible strains Variable activity against Enterobacteriaceae
4 Ceftaroline Good activity against oral anaerobes IV 600 mg every 12 h Excreted by kidneys - dose adjust in renal failure Noninferiority compared w/ vancomycin in ABSSSIs Noninferiority compared w/ ceftriaxone in CABP Safety profile similar to that of comparator drugs in clinical trials
5 Ceftaroline Well tolerated - adverse effect profile similar to other cephalosporins Can be given IM w/o causing significant pain No controlled trials in pregnancy animal studies did not find adverse effects on offspring Category B designation for use in pregnancy Not known if it is excreted in breast milk Manufacturer recommends that caution administering ceftaroline to nursing women
6 Ceftaroline Acquisition cost $80/day - favorable comparisons to other newer agents for the treatment of ABSSSI and CABP More costly than other IV cephalosporins, fluoroquinolones and vancomycin Less expensive than single-drug or combinationdrug therapy utilizing newer agents to treat MRSA - linezolid, daptomycin, or tigecycline
7 Fidaxomicin (Dificid) Nonabsorbed macrocyclic compound 1 st antimicrobial agent approved by FDA for Rx of C. difficile in last 25 years Bactericidal - mechanism of action: inhibition of a RNA polymerase 200 mg po BID not inferior to vancomycin for Rx of CDI as determined by clinical response after 10 days of Rx
8 Fidaxomicin Superior to vancomycin for sustained response w/o recurrence 25 days after Rx completion Relatively spares the indigenous fecal microbiota AEs not observed in animal reproduction studies Limited systemic absorption - exposure to fetus expected to be low Not known if it is excreted in breast milk Manufacturer recommends that caution when administering to nursing women
9 Louie, T. J., et al. (2011). "Fidaxomicin versus Vancomycin for Clostridium difficile Infection." New England Journal of Medicine 364(5):
10 Fidaxomicin VA Restrictions One of the following: Pts w/ severe CDI w/ 2 nd recurrence (previously received appropriate therapy i.e., vanc 125mg po QID for initial and 1 st recurrence) Alternatively option to prescribe vanc taper for 2 nd recurrence OR Pts w/ mild-moderate CDI with 3 rd recurrence (who previously received appropriate therapy, i.e., metronidazole 500mg po TID for initial and 1 st recurrence and then vanc taper for 2 nd recurrence)
11
12 Oritavancin (Orbactiv) Lipoglycopeptide abx with multiple mechanisms of action Inhibiting peptidoglycan cell wall synthesis Disrupting bacterial cell membrane Highly active against common gram-positive pathogens MRSA, VISA, VRSA, VRE Single IV dose of 1200 mg over 3 hours in adult patients Terminal half-life of 393 hours, repeat dosing not required for ABSSIs Very slow elimination from tissue sites No dosing adjustments required for renal, hepatic insufficiency
13 Oritavancin 2 clinical trials demonstrated noninferiority compared w/ vancomycin in the treatment of ABSSSIs AEs similar to vanc in f/u for up to 60 days Liver enzyme elevation Occurrence of osteomyelitis Pregnancy Risk Factor C - AEs not observed in animal reproduction studies Not known if it is excreted into breast milk Manufacturer recommends caution when administered to a nursing woman
14 Oritavancin Pts should be monitored for osteomyelitis and alternate Rx given in case of confirmed or suspected osteomyelitis Attractive antibiotic to consider in the outpatient area Efficacy and safety in Rx of other sites of infection yet to be established
15 Oritavancin Can reduce outpatient infusion services and home care - improve patient satisfaction Acquisition cost ($2900) may ultimately limit its use Costs in healthcare frequently limited by acquisition costs - many other associated costs are fixed or not easily reduced Occurrence of MSSA % of isolates of S. aureus β-lactam after a short inpatient course of vancomycin, telavancin, daptomycin may be a more acceptable costeffective strategy
16 Oritavancin Has not been assessed in bacteremia or bone and joint infections Resolution of reimbursement, co-pay issues along w/ cost-benefit analyses of oritavancin vs other abx used for OPAT of ABSSSIs are needed Additional clinical experience w/ response to transition therapy from other regimens needed to further assess oritavancin's role in treatment of ABSSSIs
17 Dalbavancin (Dalvance) Lipoglycopeptide w/ broad spectrum against virtually all important gram-positive pathogens Exception of vana expressing VRE Potent bactericidal agent against drug-resistant staphylococci Animal models and clinical trials - demonstrated efficacy in Rx of SSTIs Prolonged half-life of 181 h - allows for convenient once-weekly dosing
18 Dalbavancin No data to suggest clinical superiority over β - lactam abx or linezolid for infections due to susceptible organisms No sufficient data on Rx of pneumonia or bone and joint infections to draw conclusions about it s clinical usefulness for these indications Noninvolvement w/ cytochrome p450 system makes drug-drug interactions unlikely
19 Dalbavancin No serious AEs in early clinical trials Prolonged half-life - unique challenge should AEs occur Pregnancy Implications AEs have been observed in animal reproduction studies Long half-life should be considered when evaluating potential exposure to the fetus. Not known if it is excreted into breast milk Manufacturer recommends caution when administered to a nursing woman
20 Tedizolid (Sivextro) 2 nd commercially available oxazolidinone abx 1 st in class that is dosed qd Activity against wide range of gram-positive pathogens Approved to treat ABSSSIs 2 randomized controlled phase 3 trials: 6 days of tedizolid (200 mg once daily) - noninferior to 10 days of linezolid (600 mg twice daily) Differs from linezolid in incidence of GI and hematologic side fx Lacks drug interactions w/ SSRIs Conditions other than ABSSSI currently being evaluated
21 Tedizolid PO and IV tedizolid costs $235 per day. Branded IV linezolid (Zyvox) is currently $288 per day, oral $246 per day Generic intravenous linezolid relatively cheap The apparent lack of interactions with SSRIs can be a significant benefit
22 Tedizolid Pregnancy Risk Factor C AEs observed in animal reproduction studies Not known if it is excreted into breast milk Manufacturer recommends caution when administered to a nursing woman
23 Tedizolid Lack of an interaction between tedizolid and SSRIs are currently lacking clinical confirmation, as no patients in ESTABLISH-1 and -2 were on concomitant SSRIs due to the black-box warning with the comparator, linezolid Postmarketing data will need to be collected to clarify this clinical entity, as serotonin syndrome is rare and could not be studied prospectively
24 Tedizolid Linezolid does maintain certain advantages over tedizolid to date in FDA indications for: Pneumonia (nosocomial and community acquired) Complicated skin and skin structure infections (including diabetic foot infections without concomitant osteomyelitis) Uncomplicated skin and skin structure infections VRE Some physicians comfortable w/ prolonged courses of linezolid w/ close clinical monitoring Longest use of tedizolid to date is 21 days in healthy subjects
25
26 Telavancin (Vibativ) Approved (2009) for treatment of adults w/ HABP/VABP caused by susceptible isolates of S. aureus when alternative treatments are not suitable 05/09/16 FDA approval to expand the product's label to include data describing the treatment of pts w/ concurrent S. aureus bacteremia in HABP/VABP Approved for the treatment of adult pts w/ complicated skin & skin structure infections caused by susceptible isolates of Gram-positive bacteria
27 Telavancin Caveats Pts w/crcl 50 ml/min treated w/ Telavancin for HABP/VABP - increased mortality observed versus vancomycin Need to monitor renal fnx thruout therapy IV unfractionated heparin is contraindicated w/ Telavancin administration due to artificially prolonged aptt test results for up to 18 hrs after Telavancin administration
28 Telavancin Caveats Avoid in pregnancy AEs in animal developmental outcomes have been observed Women of childbearing age should have serum pregnancy test Not recommended during pregnancy unless potential benefit to mother outweighs possible risk to fetus Not known if it is excreted into breast milk Manufacturer recommends caution when administered to a nursing woman
29
30
31 Clinical decision tree to predict a bacteremic patient's likelihood of infection with an extended-spectrum β-lactamase (ESBL) producing organism at the time of organism genus and species identification. Katherine E. Goodman et al. Clin Infect Dis. 2016;cid.ciw425 The Author Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
32 Ceftolozane/tazobactam (Zerbaxa) Ceftazidime/avibactam (Avicaz) 2 novel β-lactam/β-lactamase combination abx Active against MDR gram-negatives including P. aeruginosa Ceftazidime/avibactam - active against carbapenem-resistant Enterobacteriaceae that produce Klebsiella pneumoniae carbapenemases Avibactam does not inactivate metallo-β-lactamases such as New Delhi metallo-β-lactamases
33 Ceftolozane/tazobactam (Zerbaxa) Ceftazidime/avibactam (Avicaz) Both only available as IV - dosed TID in pts w/ normal renal function Clinical trials - noninferiority to comparators of both agents when used in Rx of cutis and complicated IAIs (w/ metronidazole) Results from pneumonia studies - not yet been reported Antimicrobial stewardship - essential to preserve activity
34 Ceftolozane sulfate and Tazobactam sodium (Zerbaxa) Novel cephalosporin, w/ activity against P. aeruginosa, w/ extended spectrum betalactamase inhibitor cutis caused by E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa Combo w/ metronidazole for ciai caused by E. cloacae, E. coli, K. oxytoca, K. pneumoniae, P. mirabilis, P. aeruginosa, B. fragilis, Strep anginosus, Strep constellatus, Strep salivarius
35
36
37 Metallo-β-lactamases Diverse set of enzymes that catalyze the hydrolysis of a broad range of β-lactam drugs including carbapenems Exception - monobactams Not inhibited by mechanism-based inhibitors such as clavulanate, sulbactam, or tazobactam
38 New Delhi Metallo-beta-lactamase-1 (NDM-1) 1st found in K. pneumoniae isolate from Swedish pt in India in 2008 Died despite colistin EID Volume 19, Number 6 June NDM-producing isolates - resistant to all β- lactams, aztreonam, aminoglycosides and fluoroquinolones
39
40 Ceftolozane sulfate and Tazobactam sodium Pregnancy Risk Factor B - AEs observed in some animal reproduction studies Tazobactam crosses the placenta Not known if ceftolozane or tazobactam are excreted into breast milk Manufacturer recommends caution if administered to a nursing woman
41 Ceftazidime/avibactam (Avicaz) Avibactam - novel, non β-lactam β-lactamase inhibitor that restores the in vitro activity of the established extended-spectrum antipseudomonal cephalosporin, ceftazidime, against Ambler class A, class C, and some class D β-lactamase producing pathogens
42
43 Ceftazidime/avibactam In phase 2 trials - effective and well tolerated in pts w/ ciai (in combo w/ metronidazole) and cutis Based on these data - approved by FDA for Rx of ciai (in combo w/ metronidazole) and cutis (including pyelonephritis) in adults w/ limited or no alternative Rx options
44 Ceftazidime/avibactam Pregnancy Implications AEs not been observed in animal reproduction studies conducted with ceftazidime AEs observed in some animal reproduction studies conducted with avibactam. Ceftazidime is excreted in breast milk Not known if avibactam is excreted in breast milk Manufacturer recommends caution when administering ceftazidime and avibactam to breast-feeding women
45
46 Difference in clinical cure rates at test-of-cure (TOC) visit by renal function. John E. Mazuski et al. Clin Infect Dis. 2016;62: The Author Published by Oxford University Press for the Infectious Diseases Society of America.
47
48 van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-lactam/β-lactamase Combinations. Clin Infect Dis. 2016;63(2):
49 No commercial sensitivity testing for the top 6 below Research use only disk Surrogate Pharma-Supported Research lab
50
51
52 Peramivir 2009 Emergency Use ~ 1274 hospitalized pts Rxed w/ IV peramivir thru the EUA program during the pandemic Mostly critically ill, white adults w/ underlying medical conditions who had been treated initially w/ oral oseltamivir and subsequently treated late in the clinical course with peramivir for ~ 1 wk Hard to interpret results
53 Peramivir Potential Indications N/V/D, or other GI sensitivity Requiring IV for rehydration or other meds Pts preferring a single-dose Rx administered by a healthcare provider Pts who otherwise cannot be prescribed oral or inhaled, multi-dose therapies
54 Peramivir Pregnancy Risk Factor C AEs observed in some animal reproduction studies Information related to the use of peramivir in pregnancy is limited Based on information from one case, the pharmacokinetics of peramivir may be changed with pregnancy
55 Peramivir Untreated influenza - associated with increased risk of AEs to the fetus and increased risk of complications or death to the mother Neuraminidase inhibitors are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks postpartum Not known if peramivir is excreted into breast milk Manufacturer - decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother
56 Isavuconazole (Cresemba) Extended spectrum triazole with activity against yeasts, molds, dimorphic fungi Approved for treatment of invasive aspergillosis and mucormycosis Advantages Availability of a water-soluble IV formulation Excellent bioavailability of the oral formulation Predictable pharmacokinetics in adults
57 Isavuconazole Mechanism of Action Inhibits cytochrome P450 dependent 14α-lanosterol demethylation Essential for fungal cell membrane ergosterol synthesis This blockade produces methylated sterols in the fungal membrane - accumulation of ergosterol toxic precursors in the cytoplasm, which leads to cell death Side arm of the active isavuconazole molecule allows greater avidity for the binding pocket in the fungal CYP51 protein, conferring broader antifungal spectrum even to pathogens resistant to other azoles
58 Isavuconazole Drug-Drug Interactions Substrate for CYP3A4 - inhibitors of this enzyme lead to increased levels of isavuconazole Rifampin, carbamazepine, long-acting barbituates Should not be used with this antifungal Moderate inhibitor of CYP3A4 Higher levels of sirolimus, tacrolimus, cyclosporine Serum levels need to be monitored Minimal effect on CYP2C9 and CYP2C19, No dosage adjustment of warfarin and omeprazole Overall compared with voriconazole and posaconazole Isavuconazole seems to have fewer drug-drug interactions
59 Isavuconazole Side Effects Relatively safe and well tolerated Most common N/V/D, rarely have led to discontinuation <15% - HA, rash, peripheral edema No voriconazole side effects - visual disturbances, hallucinations, photosensitivity
60 Isavuconazole Liver enzymes should be monitored Infusion reactions in a few pts - acute respiratory distress, chills, dyspnea, hypotension Recommend in-line filter be used for infusion Pregnancy Risk Factor C AEs observed in animal reproduction studies Not known if it is excreted into breast milk Breast-feeding not recommended by manufacturer
61 Restricting Fluoroquinolone Use FDA Serious side f/x ass. w/ fluoroquinolones generally outweigh benefits for pts w/ acute sinusitis, acute bronchitis, uncomplicated UTIs who have other Rx options Tendons, muscles, joints, nerves, CNS Fluoroquinolones should be reserved for those who do not have alternative Rx options
62
63
64
65
66 On The Verge Solithromycin - next-generation IV/po fluoroketolide in Phase 3 studies for Rx of moderate to moderatelysevere CABP and urethritis Fusidic acid bacteriostatic protein synthesis inhibitor used topically being investigated for IV/oral use Delafloxacin fluoroquinolone more active (lower MIC90) than other quinolones against MRSA In contrast to other fluoroquinolones, which are zwitterionic, delafloxacin has an anionic character, which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic ph
67 On The Verge Lefamulin pleuromutilin in Phase 2 studies Inhibits bacterial growth by binding to specific site on the bacterial ribosome Brilacidin - novel defensin mimetic in Phase 2 studies Omadacycline aminomethylcycline derived from tetracyclines in Phase 3 IV/po qd w/activity against Gram-positive, Gramnegative, atypical and anaerobic bacteria
68 References Burdette SD, Trotman R. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. Clin Infect Dis Oct 15;61(8): Saravolatz LD, Stein GE. Oritavancin: A Long-Half-Life Lipoglycopeptide. Clin Infect Dis Aug 15;61(4): Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis Feb 15;46(4): van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-lactam/β-lactamase Combinations. Clin Infect Dis Apr 20.epub Center for Disease Dynamics, Economics & Policy State of the World s Antibiotics, CDDEP: Washington, DC. Deak, D., et al. (2016). "Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration Approved Antibiotics, FDA-Approved Antibiotics, " Annals of Internal Medicine Online May 31,2016.
69 References Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis May;52(9): Louie, T. J., et al. (2011). "Fidaxomicin versus Vancomycin for Clostridium difficile Infection." New England Journal of Medicine 364(5): Moran, Gregory J et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, doubleblind, phase 3, non-inferiority trial. The Lancet Infectious Diseases, Volume 14, Issue 8, Rubinstein, E., et al. (2011). "Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens." Clin Infect Dis 52(1): Maertens, Johan A et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet, Volume 387, Issue 10020, Humphries, R. M. and J. A. Hindler (2016). "Emerging Resistance, New Antimicrobial Agents but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape." Clinical Infectious Diseases 63(1):
ESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationNEW ANTIMICROBIALS. Sarah McClain, PharmD, BCPS Infectious Diseases Pharmacy Resident Carilion Clinic Roanoke Memorial Hospital April 17, 2015
NEW ANTIMICROBIALS Sarah McClain, PharmD, BCPS Infectious Diseases Pharmacy Resident Carilion Clinic Roanoke Memorial Hospital April 17, 2015 DISCLOSURES I have no disclosures or conflicts of interest.
More informationInfectious Disease in the Critically Ill Patient
Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:
More informationOther β-lactam. A. Carbapenems:
A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,
More informationNew Antimicrobials: Now and In the Future
New Antimicrobials: Now and In the Future David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School Conflicts of Interest Melinta
More informationCE Prn. Pharmacy Continuing Education from WF Professional Associates ABOUT WFPA LESSONS TOPICS ORDER CONTACT PHARMACY EXAM REVIEWS
CE Prn Pharmacy Continuing Education from WF Professional Associates ABOUT WFPA LESSONS TOPICS ORDER CONTACT PHARMACY EXAM REVIEWS New Antimicrobials March 2016 Drug resistant infections are becoming more
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationVIII Updating Course of Antimicrobials and Infectious Diseases 2018
The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
More informationAntibiotics to treat multi-drug-resistant bacterial infections
Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1 Forward Looking Statements and Other Important Cautions Any statements
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationOptions for Complicated Skin and Skin Structure Infections. Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ.
Options for Complicated Skin and Skin Structure Infections Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator for,
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More informationXERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy Disclosures
More informationMICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
More informationAntimicrobial Agent Update
Antimicrobial Agent Update Michael J. Tan, MD, FACP, FIDSA Associate Professor of Internal Medicine, Northeastern Ohio Medical University Clinical Physician, Infectious Diseases and HIV, Summa Health System
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationInnovations in Antimicrobials Something Old, Something New
FSHP Disclosure Innovations in Antimicrobials Something Old, Something New Harrison Bachmeier, PharmD, BCPS Pharmacist Specialist-Infectious Diseases LeeHealth Fort Myers & Cape Coral, FL I do not have
More informationInitial U.S. Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEFLARO safely and effectively. See full prescribing information for TEFLARO. TEFLARO (ceftaroline
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationWhat's New in Infectious Diseases Pharmacotherapy?
Disclosure What's New in Infectious Diseases Pharmacotherapy? Nothing to Disclose Douglas Slain, Pharm.D., BCPS, FCCP, FASHP Associate Professor Infectious Diseases Clinical Specialist West Virginia University
More informationNEW DRUGS PART II 7/7/ ANNUAL MEETING ANTIBIOTICS AND ANTIFUNGALS DISCLOSURE BACTERIA OBJECTIVES ANTIBIOTIC RESISTANCE
ANTIBIOTICS AND ANTIFUNGALS NEW DRUGS PART II JACQUELINE KING, PHARM.D. PHARMACY OPERATIONS SUPERVISOR UFHEALTH CANCER CENTER JACQUELINE.KING@ORLANDOHEALTH.COM TARA MCNULTY, CPHT, RPHT PROJECT MANAGER
More informationConflicts and Disclosures. Hot Topics & Key Articles in Infectious Diseases 3/15/2017. Hot Topics in Infectious Diseases
Hot Topics & Key Articles in Infectious Diseases Conflicts and Disclosures I have nothing to disclose. Kim S. Erlich, M.D. Associate Clinical Professor, UCSF Chief of Staff Medical Director of Infection
More informationAntibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:
Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Michael Satlin, MD, MS Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medicine March 4, 2016 1 Disclosures
More informationHepatitis C Treatment and the Role of the Pharmacist
Infectious Diseases Odds and Ends: Focus on Developments in Hepatology and Gram-Negative Infections Lindsey Childs-Kean, PharmD, MPH, BCPS Clinical Assistant Professor University of Florida College of
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationNew Antimicrobials & Agents in the Pipeline
New Antimicrobials & Agents in the Pipeline Keenan Ryan, PharmD PGY2 Pharmacy Resident in Infec=ous Diseases University of New Mexico College of Pharmacy October 2015 Learning Objectives By the end of
More informationWARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS
DECLESAU (dergrafloxacin) tablets, for oral use DECLESAU (dergrafloxacin) injection, solution for intravenous use WARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including
More informationNew Antimicrobials & Agents in the Pipeline
Learning Objectives New Antimicrobials & Agents in the Pipeline Keenan Ryan, PharmD PGY2 Pharmacy Resident in Infec=ous Diseases University of New Mexico College of Pharmacy October 2015 By the end of
More information400 mg IV (over 5 to 60 minutes) every 12 hours. > 30 to mg IV (over 5 to 60 minutes ) every 12 hours. 15 to 30
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEFLARO safely and effectively. See full prescribing information for TEFLARO. TEFLARO (ceftaroline
More informationarguably the greatest risk to human health comes in the form of antibiotic-resistant bacteria. We live in a bacterial world where we will never be
arguably the greatest risk to human health comes in the form of antibiotic-resistant bacteria. We live in a bacterial world where we will never be able to stay ahead of the mutation curve. A test of our
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationgram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium
Mickey Dufilho s Drugs and Bugs Revised 10/10/15 Bacteria Drugs that Inhibit Cell Wall Synthesis Drug Action Spectrum of Action Comments Spectrum of Action Bacitracin Beta-Lactam antibiotics Penicillin
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationProtein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8
Protein Synthesis Inhibitors Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 These drugs selectively inhibit bacterial protein synthesis. The selectivity is due to the differences between bacterial and human
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationHOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA. Romney Humphries, PhD D(ABMM)
HOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu WHAT WE WILL
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationMacrolides & Ketolides. Objectives. Protein Synthesis
Macrolides & Ketolides Elizabeth D. Hermsen, Pharm.D. Infectious Diseases Research Fellow University of Minnesota College of Pharmacy bjectives Participant should be able to explain macrolide/ketolide
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More informationNEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES
Lisa G. Winston, MD Professor, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital Epidemiologist, San Francisco General Hospital NEW DEVELOPMENTS AND CHALLENGING
More informationResistance to new anti-grampositive. Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France
Resistance to new anti-grampositive agents Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France Recently available antimicrobials against MDR Gram-positive infections Cyclic lipopeptide: daptomycin
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ZERBAXA. Ceftolozane and Tazobactam powder for injection
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ZERBAXA Ceftolozane and Tazobactam powder for injection 1.5 gram (g) per vial Containing ceftolozane 1 g (as ceftolozane sulfate) and tazobactam
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal catastrophes in ICU, 1017 1044. See also specific types, e.g., Abdominal compartment syndrome treatment of, 1032 1037 antimicrobial,
More informationOTE. Peramivir: A Novel Intravenous Neuraminidase Inhibitor for the Treatment of Influenza. Vol. 30, Issue 9 June 2015.
HAR Vol. 30, Issue 9 June 2015 M A N OTE Established 1985 Peramivir: A Novel Intravenous Neuraminidase Inhibitor for the Treatment of Influenza Vincent Solomon, PharmD Peramivir: A Novel Intravenous Neuraminidase
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationAchaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cuti)
Achaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cuti) -- ZEMDRI now available for ordering in the U.S. -- -- ZEMDRI demonstrated in vitro
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationCubicin A Guide to Dosing
Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections
More informationInfections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationXerava (eravacycline) NEW PRODUCT SLIDESHOW
Xerava (eravacycline) NEW PRODUCT SLIDESHOW Introduction Brand name: Xerava Generic name: Eravacycline Pharmacological class: Tetracycline antibiotic Strength and Formulation: 50mg; per vial; lyophilized
More informationSummary of the risk management plan (RMP) for Cresemba (isavuconazole)
EMA/576866/2015 Summary of the risk management plan (RMP) for Cresemba (isavuconazole) This is a summary of the risk management plan (RMP) for Cresemba, which details the measures to be taken in order
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationClostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure
Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationVancomycin Orion , Version 2 Public Summary of the Risk Management Plan
Vancomycin Orion 18.1.2016, Version 2 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationAciphin Ceftriaxone Sodium
Aciphin Ceftriaxone Sodium Only for the use of Medical Professionals Description Aciphin is a bactericidal, long-acting, broad spectrum, parenteral cephalosporin preparation, active against a wide range
More informationAdult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
More informationClinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
Clin Pharmacokinet (2018) 57:797 816 https://doi.org/10.1007/s40262-017-0623-4 REVIEW ARTICLE Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides Valentin
More informationROSOBAC-1GM / ROSOBAC-FORT
ROSOBAC-1GM / ROSOBAC-FORT ROSOBAC - 1GM. COMPOSITION : Each vial contains Sterile Cefoperazone Sodium IP Eq. to Anhydrous Cefoperazone - Sterile Sulbactam Sodium USP Eq. to Anhydrous Sulbactam - ROSOBAC
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM. Oxiconazole Nitrate Cream
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM Oxiconazole Nitrate Cream QUALITATIVE AND QUANTITATIVE COMPOSITION ZODERM E CREAM contains: Oxiconazole
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationNew Medicines Committee Briefing. July Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection
New Medicines Committee Briefing July 2014 Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection (unlicensed indication) Fosfomycin trometamol to be reviewed for use within:
More informationCeftolozane/tazobactam (Zerbaxa, Merck) September 2015 Inpatient Non-Formulary
Ceftolozane/tazobactam (Zerbaxa, Merck) September 2015 Inpatient n-formulary Criteria for Formulary Consideration of Ceftolozane/tazobactam Efficacy Ceftolozane/tazobactam was approved by the Food and
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY Volume 23 Number 6 June 2017 C Ceftaroline: An Alternative Broad Spectrum Antibiotic for Pediatric Infections Marcia L. Buck, PharmD, FCCP, FPPAG, BCPPS eftaroline was approved
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationAnti-Microbial Drugs
Name: Date: Monday March 7 th 2011 Class: I "Pharmacology Anti-Microbial Drugs Lecture 5 د. حيدر الشكرجي Macrolides: Anti-Microbial Drugs Erythromycin was the 1 st of macrolides to find clinical application,
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationlife-threatening infections
Vancomycin Vancomycin has become increasingly important in the treatment of life-threatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal
More informationPART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO
PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO This is a summary of the risk management plan (RMP) for ZINFORO. The RMP details important risks of ZINFORO, how
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationVancomycin Orion , Version 1.0. Public Summary of the Risk Management Plan
Vancomycin Orion 18.6.2015, Version 1.0 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationNew treatments of multidrug-resistant Gram-negative ventilatorassociated
Review Article Page 1 of 22 New treatments of multidrug-resistant Gram-negative ventilatorassociated pneumonia Garyphallia Poulakou 1, Styliani Lagou 1, Drosos E. Karageorgopoulos 2, George Dimopoulos
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationJill Michaud, Pharm.D., BCPS. I have no actual or potential conflicts of interest related to this presentation
Jill Michaud, Pharm.D., BCPS I have no actual or potential conflicts of interest related to this presentation Focus New drugs you might use in the Emergency department New drugs patients might be on Indications
More informationLa neutropenia febbrile
XII Corso Avanzato di Terapia Antibiotica Pisa, 15-16 novembre 2017 La neutropenia febbrile Alessandra Micozzi Dipartimento di Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Fever developing
More informationThe Curious Intersection of HIV and Staphylococcus aureus with a Focus on MRSA
The Curious Intersection of HIV and Staphylococcus aureus with a Focus on MRSA Franklin D. Lowy, MD Columbia University College of Physicians & Surgeons New York, NY Topics to Be Covered Background Some
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationExtrapolation in antibacterial agents
Extrapolation in antibacterial agents Irja Lutsar University of Tartu, Estonia Maria Fernandez Cortizo- Medicines Agency, Spain EMA meeting, 30.09.2015 Glossary PIP: Paediatric Investigation Plan AHOM:
More informationAVYCAZ (ceftazidime and avibactam) for injection, for intravenous use Initial U.S. Approval: 2015
HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVYCAZ safely and effectively. See full prescribing information
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME Zinforo 600 mg powder for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains ceftaroline fosamil acetic acid solvate monohydrate equivalent
More informationPlazomicin for complicated urinary tract infection
October 2016 Horizon Scanning Research & Intelligence Centre Plazomicin for complicated urinary tract infection NIHR HSRIC ID: 9787 Lay summary Serious infections caused by Gram-negative bacteria are becoming
More informationUniversity of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationInfections Amenable to OPAT. (Nabin Shrestha + Ajay Mathur)
3 Infections Amenable to OPAT (Nabin Shrestha + Ajay Mathur) Decisions regarding outpatient treatment of infections vary with the institution, the prescribing physician, the individual patient s condition
More informationAcute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016
Acute Cholangitis Kelsey Knotts PharmD Candidate Class of 2016 Learning Objectives 1. Describe the mechanism of the development of acute cholangitis 2. Identify common causative organisms in acute cholangitis
More informationZinplava. (bezlotoxumab) New Product Slideshow
Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More information